Loading clinical trials...

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials | Clinical Trials | Clareo Health

RECRUITINGNA

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Randomized Trial of Recruitment Strategies for Early Phase Therapeutic Cancer Trials

NCT05886764•University of Chicago

Summary

This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interventions or no intervention (control arm).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 18 years or older
•Self-described African American race (patients who self-describe as "more than one race" will be included)
•Scheduled for new or consult oncology appointment at the study site
•Scheduled for return outpatient oncology appointment at the study site with a biopsy or radiology encounter within 2 weeks prior to provider visit.
•* for prostate cancer patients: 2 or more increasing prostate specific antigen (PSA) values i the 6 months prior to visit
•other patient identified by research team as potentially having a change in treatment prior to next outpatient oncology appointment at the study site
•oncology provider at study site scheduled to see patients meeting criteria above

Exclusion Criteria

•Estimated glomerular filtration rate (GFR) less than 30 ml/min/1.73m2 documented within last 2 months and without documented resolutions
•Bilirubin greater than 3.0 ng/dl documented within last 2 months and without documented resolution
•Initiated new anti-cancer therapy within last 2 months
•Evaluated for possible enrollment/randomization in the last 2 months
•Prior enrollment/randomization on this recruitment trial

Locations (1)

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

Key Dates

Start Date

October 23, 2023

Primary Completion Date

January 26, 2026

Completion Date

July 1, 2027

Last Updated

March 6, 2026

Enrollment

180

ESTIMATED participants

Conditions

CancerMalignancyMalignant Neoplasm

Interventions

Digital Intervention

OTHER

Community Outreach

OTHER

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients